Chemotherapy of cervix cancer with doxorubicin and cisplatin: A phase I pilot study of the Gynecologic Oncology Group

G. A. Omura, J. Hubbard, K. Hatch

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Twelve women with previously irradiated advanced pelvic cancer were treated with doxorubicin and cisplatin to determine a maximum tolerable dose. Response was not an objective of this phase 1 study, but one partial response was seen in four cases of cervix cancer with measurable lesions. Hematologic toxicity was frequent and severe at the starting doses (doxorubicin 30 mg/M2 and cisplatin 100 mg/M2 every 3 weeks), but was acceptable when cisplatin was used at 75 mg/M2. Further evaluation of this combination in squamous carcinoma of the cervix is not recommended.

Original languageEnglish (US)
Pages (from-to)347-349
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume8
Issue number5
DOIs
StatePublished - 1985
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Chemotherapy of cervix cancer with doxorubicin and cisplatin: A phase I pilot study of the Gynecologic Oncology Group'. Together they form a unique fingerprint.

Cite this